-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-1434 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-1434 in Solid Tumor Drug Details: FP1-1434 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Letrozole in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Letrozole in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Letrozole in Breast Cancer Drug Details: Letrozole (Letrozole Quarterly) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Povorcitinib Phosphate in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Povorcitinib Phosphate in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Povorcitinib Phosphate in Vitiligo Drug Details: Povorcitinib (INCB-54707) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bezuclastinib in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bezuclastinib in Gastrointestinal Stromal Tumor (GIST) Drug Details: Bezuclastinib...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bezuclastinib in Systemic Mastocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bezuclastinib in Systemic Mastocytosis Drug Details: Bezuclastinib (CGT-9486) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISM-012042 in Inflammatory Bowel Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISM-012042 in Inflammatory Bowel Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISM-012042 in Inflammatory Bowel Disease Drug Details: ISM012-042 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISM-3091 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISM-3091 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISM-3091 in Metastatic Breast Cancer Drug Details: ISM-3091 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISM-3091 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISM-3091 in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISM-3091 in Metastatic Ovarian Cancer Drug Details: ISM-3091 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISM-3091 in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISM-3091 in Metastatic Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISM-3091 in Metastatic Prostate Cancer Drug Details: ISM-3091 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISM-001 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISM-001 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ISM-001 in Idiopathic Pulmonary Fibrosis Drug Details:ISM-001055 is under development for the...